Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups (This dataset does not contain this module)
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines (This dataset does not contain this module)
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors (This dataset does not contain this module)

Dataset: GSE161195

Dataset summary for GSE161195

Datast information	Dataset	GSE161195
	PMID	33619369
	Raw data ID/link	PRJNA675855
	Organism	Homo sapiens
	Source	patients
	Tissue	Bone marrow aspirate
	Cancer type level1	Multiple myeloma
	Cancer type level2	Refractory multiple myeloma (MM)
	Regimen	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)
	Drug type	Targeted therapy
	Sample size	pre (resistant 7, sensitive 21); post (resistant 5, sensitive 15)
	Cell number	36505
	Extract protocol	MARS-seq v2.0
	Data processing	NA
	Public date	Public on Jan 27, 2021
	Description	This dataset has 28 patients, 19 of whom have both pre- and post-treatment samples.

Top

Drug summary for GSE161195

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"Daratumumab"	DB09331	biotech	CD38	P28907
"Carfilzomib"	DB08889	small molecule	PSMB5; PSMB8; PSMB1; PSMB9; PSMB2; PSMB10	P28074; P28062; P20618; P28065; P49721; P40306
"Lenalidomide"	DB00480	small molecule	CRBN; TNFSF11; CDH5; PTGS2	Q96SW2; O14788; P33151; P35354
"Dexamethasone"	DB01234	small molecule	NR3C1; NR0B1; ANXA1; NOS2; NR1I2	P04150; P51843; P04083; P35228; O75469

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types

Umap of conditions

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
ITGB7	ENSG00000139626	0.985106	0.00e+00	0.00e+00	0.368	0.147	Malignant cells	pre
MT-CO3	ENSG00000198938	0.896265	0.00e+00	0.00e+00	1	0.998	Malignant cells	pre
HIST1H4C	NA	0.750632	0.00e+00	0.00e+00	0.291	0.163	Malignant cells	pre
TUBA1B	ENSG00000123416	0.738956	0.00e+00	0.00e+00	0.37	0.153	Malignant cells	pre
TMSB4X	ENSG00000205542	0.577442	0.00e+00	0.00e+00	0.346	0.256	Malignant cells	pre
LILRB4	ENSG00000278555	0.564978	0.00e+00	0.00e+00	0.272	0.035	Malignant cells	pre
PPIA	ENSG00000196262	0.554544	0.00e+00	0.00e+00	0.505	0.33	Malignant cells	pre
MT-CO2	ENSG00000198712	0.546375	0.00e+00	0.00e+00	1	0.998	Malignant cells	pre
TMSB10	ENSG00000034510	0.51781	0.00e+00	0.00e+00	0.688	0.529	Malignant cells	pre
MT-TG	ENSG00000210164	0.508741	0.00e+00	0.00e+00	0.866	0.756	Malignant cells	pre
FTL	ENSG00000087086	0.505872	0.00e+00	0.00e+00	0.901	0.871	Malignant cells	pre
MT-CO1	ENSG00000198804	0.504297	0.00e+00	0.00e+00	0.999	0.998	Malignant cells	pre
GAPDH	ENSG00000111640	0.493641	0.00e+00	0.00e+00	0.531	0.376	Malignant cells	pre
COX6C	ENSG00000164919	0.471664	0.00e+00	0.00e+00	0.455	0.26	Malignant cells	pre
LDHA	ENSG00000288299	0.403334	0.00e+00	0.00e+00	0.376	0.201	Malignant cells	pre
MYDGF	ENSG00000074842	0.399788	3.52e-33	6.50e-29	0.357	0.316	Malignant cells	pre
RAN	ENSG00000132341	0.388483	0.00e+00	0.00e+00	0.357	0.184	Malignant cells	pre
H2AFZ	NA	0.365777	0.00e+00	0.00e+00	0.293	0.155	Malignant cells	pre
MT-ND4	ENSG00000198886	0.358804	0.00e+00	0.00e+00	1	0.999	Malignant cells	pre
RPL38	ENSG00000172809	0.354527	0.00e+00	0.00e+00	0.893	0.805	Malignant cells	pre
RPLP0	ENSG00000089157	0.339328	0.00e+00	0.00e+00	0.938	0.865	Malignant cells	pre
RPL27	ENSG00000131469	0.335115	0.00e+00	0.00e+00	0.91	0.843	Malignant cells	pre
YBX1	ENSG00000065978	0.329896	0.00e+00	0.00e+00	0.436	0.304	Malignant cells	pre
ACTG1	ENSG00000184009	0.32097	0.00e+00	0.00e+00	0.512	0.402	Malignant cells	pre
HSP90AA1	ENSG00000080824	0.318902	0.00e+00	0.00e+00	0.365	0.279	Malignant cells	pre
MTCO2P12	ENSG00000229344	0.311068	0.00e+00	0.00e+00	0.711	0.628	Malignant cells	pre
MTCO1P12	ENSG00000237973	0.304797	0.00e+00	0.00e+00	0.653	0.545	Malignant cells	pre
PTMA	ENSG00000187514	0.304547	0.00e+00	0.00e+00	0.54	0.47	Malignant cells	pre
HLA-A	ENSG00000227715	0.29807	0.00e+00	0.00e+00	0.754	0.674	Malignant cells	pre
RPS24P8	ENSG00000224094	0.297747	0.00e+00	0.00e+00	0.303	0.16	Malignant cells	pre
ATP5E	NA	0.2899	0.00e+00	0.00e+00	0.63	0.531	Malignant cells	pre
ATP5J2	NA	0.288403	0.00e+00	0.00e+00	0.301	0.186	Malignant cells	pre
ENO1	ENSG00000074800	0.287451	0.00e+00	0.00e+00	0.251	0.129	Malignant cells	pre
SUB1	ENSG00000113387	0.285626	0.00e+00	0.00e+00	0.749	0.694	Malignant cells	pre
NDUFB9	ENSG00000147684	0.282287	0.00e+00	0.00e+00	0.271	0.145	Malignant cells	pre
IGHA2	ENSG00000276173	0.280265	0.00e+00	0.00e+00	0.322	0.163	Malignant cells	pre
OAZ1	ENSG00000104904	0.274302	0.00e+00	0.00e+00	0.498	0.429	Malignant cells	pre
RPS29	ENSG00000213741	0.272573	0.00e+00	7.01e-44	0.899	0.877	Malignant cells	pre
CHCHD2	ENSG00000106153	0.270793	0.00e+00	0.00e+00	0.345	0.246	Malignant cells	pre
NME2	ENSG00000243678	0.259249	0.00e+00	0.00e+00	0.531	0.432	Malignant cells	pre
CALM2	ENSG00000143933	0.254008	0.00e+00	0.00e+00	0.322	0.236	Malignant cells	pre
MIF	ENSG00000276701	0.253408	0.00e+00	1.92e-42	0.517	0.456	Malignant cells	pre
MT-ND1	ENSG00000198888	0.250751	0.00e+00	0.00e+00	0.996	0.993	Malignant cells	pre
NUCB2	ENSG00000070081	-0.250725	0.00e+00	0.00e+00	0.29	0.432	Malignant cells	pre
FAM46C	NA	-0.253999	0.00e+00	0.00e+00	0.3	0.457	Malignant cells	pre
BLOC1S5-TXNDC5	ENSG00000259040	-0.255148	0.00e+00	0.00e+00	0.878	0.957	Malignant cells	pre
POU2AF1	ENSG00000110777	-0.260602	0.00e+00	0.00e+00	0.169	0.312	Malignant cells	pre
CYBA	ENSG00000051523	-0.267095	0.00e+00	0.00e+00	0.35	0.459	Malignant cells	pre
AC134669.2	NA	-0.273953	0.00e+00	0.00e+00	0.207	0.352	Malignant cells	pre
RPL36AL	ENSG00000165502	-0.282286	0.00e+00	0.00e+00	0.425	0.549	Malignant cells	pre

Page: 1 2

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
SLC25A5	ENSG00000005022	0.416393	0.00e+00	0.00e+00	0.451	0.213	Malignant cells	post
CBX3	ENSG00000122565	0.415554	0.00e+00	0.00e+00	0.38	0.167	Malignant cells	post
HSPB1	ENSG00000106211	0.414615	0.00e+00	0.00e+00	0.298	0.068	Malignant cells	post
RPS19	ENSG00000105372	0.414452	0.00e+00	0.00e+00	0.958	0.919	Malignant cells	post
TXN	ENSG00000136810	0.414107	0.00e+00	0.00e+00	0.56	0.36	Malignant cells	post
MIR1244-1	ENSG00000284378	0.410006	0.00e+00	0.00e+00	0.514	0.289	Malignant cells	post
RPLP1	ENSG00000137818	0.40895	0.00e+00	0.00e+00	0.997	0.99	Malignant cells	post
RPS13	ENSG00000110700	0.406467	0.00e+00	0.00e+00	0.921	0.834	Malignant cells	post
RPS6	ENSG00000137154	0.403376	4.33e-41	8.00e-37	0.955	0.932	Malignant cells	post
RPL23	ENSG00000125691	0.398118	0.00e+00	1.40e-45	0.936	0.895	Malignant cells	post
HSPE1	ENSG00000115541	0.394188	0.00e+00	0.00e+00	0.356	0.136	Malignant cells	post
AC026403.1	NA	0.392101	0.00e+00	0.00e+00	0.544	0.329	Malignant cells	post
NDUFA4	ENSG00000189043	0.391665	0.00e+00	0.00e+00	0.502	0.343	Malignant cells	post
LILRB4	ENSG00000278555	0.391486	0.00e+00	0.00e+00	0.297	0.085	Malignant cells	post
CYCS	ENSG00000172115	0.389507	0.00e+00	0.00e+00	0.356	0.195	Malignant cells	post
NDUFB2	ENSG00000090266	0.38371	0.00e+00	0.00e+00	0.345	0.141	Malignant cells	post
EIF3H	ENSG00000147677	0.378992	0.00e+00	0.00e+00	0.411	0.234	Malignant cells	post
SNHG6	ENSG00000245910	0.376594	0.00e+00	0.00e+00	0.378	0.182	Malignant cells	post
JTB	ENSG00000143543	0.376182	0.00e+00	0.00e+00	0.494	0.284	Malignant cells	post
RPS17	ENSG00000278229	0.372772	0.00e+00	0.00e+00	0.928	0.849	Malignant cells	post
BX679664.3	NA	0.371037	0.00e+00	0.00e+00	0.352	0.139	Malignant cells	post
PPA1	ENSG00000180817	0.369965	0.00e+00	0.00e+00	0.379	0.177	Malignant cells	post
SNORA33	ENSG00000200534	0.368771	0.00e+00	0.00e+00	0.75	0.587	Malignant cells	post
GAPDH	ENSG00000111640	0.359637	0.00e+00	0.00e+00	0.643	0.457	Malignant cells	post
UBA52	ENSG00000221983	0.357562	0.00e+00	0.00e+00	0.856	0.777	Malignant cells	post
RPL31	ENSG00000071082	0.356669	0.00e+00	0.00e+00	0.942	0.889	Malignant cells	post
UQCRQ	ENSG00000164405	0.352777	0.00e+00	0.00e+00	0.484	0.286	Malignant cells	post
NAP1L1	ENSG00000187109	0.34998	0.00e+00	1.61e-43	0.495	0.345	Malignant cells	post
PDCD5	ENSG00000105185	0.3494	0.00e+00	0.00e+00	0.348	0.137	Malignant cells	post
HMGB2	ENSG00000164104	0.348286	0.00e+00	0.00e+00	0.288	0.089	Malignant cells	post
COX7B	ENSG00000131174	0.345977	0.00e+00	0.00e+00	0.387	0.182	Malignant cells	post
SOD1	ENSG00000142168	0.343696	0.00e+00	0.00e+00	0.394	0.21	Malignant cells	post
UQCRB	ENSG00000156467	0.34235	0.00e+00	0.00e+00	0.546	0.378	Malignant cells	post
H3F3AP6	NA	0.340236	0.00e+00	0.00e+00	0.418	0.248	Malignant cells	post
RPS27A	ENSG00000143947	0.336687	0.00e+00	0.00e+00	0.946	0.912	Malignant cells	post
COX6B1	ENSG00000126267	0.334223	0.00e+00	0.00e+00	0.471	0.26	Malignant cells	post
SEC61G	ENSG00000132432	0.333788	0.00e+00	0.00e+00	0.487	0.31	Malignant cells	post
SNRPE	ENSG00000182004	0.331671	0.00e+00	0.00e+00	0.273	0.095	Malignant cells	post
TUBB	ENSG00000235067	0.331062	0.00e+00	0.00e+00	0.321	0.162	Malignant cells	post
EIF3E	ENSG00000104408	0.329682	0.00e+00	0.00e+00	0.398	0.247	Malignant cells	post
NDUFB9	ENSG00000147684	0.325283	0.00e+00	0.00e+00	0.353	0.165	Malignant cells	post
RPS5	ENSG00000083845	0.32487	2.58e-25	4.76e-21	0.785	0.742	Malignant cells	post
ACTG1	ENSG00000184009	0.321289	7.79e-39	1.44e-34	0.65	0.526	Malignant cells	post
NDUFA1	ENSG00000125356	0.321134	0.00e+00	0.00e+00	0.503	0.328	Malignant cells	post
PTMAP4	ENSG00000231503	0.316164	0.00e+00	0.00e+00	0.5	0.335	Malignant cells	post
HIST1H1C	NA	0.314706	0.00e+00	0.00e+00	0.267	0.124	Malignant cells	post
HSPD1	ENSG00000144381	0.313801	0.00e+00	0.00e+00	0.324	0.134	Malignant cells	post
CHCHD2	ENSG00000106153	0.313764	0.00e+00	0.00e+00	0.482	0.313	Malignant cells	post
CALM2	ENSG00000143933	0.312745	0.00e+00	0.00e+00	0.42	0.248	Malignant cells	post
ANP32E	ENSG00000143401	0.311245	0.00e+00	0.00e+00	0.261	0.092	Malignant cells	post

Page: 1 2 3 4

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug-resistant mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	5.00e-03	2.50e-02	97	781	9	23467	Malignant cells	HSPA5,CCND1,HSP90B1,FTL,GAPDH,LDHA,TPT1,YBX1,ENO1
Epigenetic Alteration of DNA, RNA or Protein	5.60e-01	1.00e+00	97	455	2	23467	Malignant cells	GAPDH,MT-CO2
Aberration of the Drug's Therapeutic Target	1.00e+00	1.00e+00	97	90	0	23467	Malignant cells
Drug Inactivation by Structure Modification	1.00e+00	1.00e+00	97	27	0	23467	Malignant cells
Irregularity in Drug Uptake and Drug Efflux	1.00e+00	1.00e+00	97	37	0	23467	Malignant cells

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	2.80e-05	1.40e-04	194	781	19	23467	Malignant cells	CFLAR,GSTP1,RPS6,S100A4,STMN1,SLC25A5,HSPD1,GAPDH,HMGB2,HSPB1,LDHA,PABPC1,S100A11,SMC4,TPT1,YBX1,ENO1,GNAS,NPM1
Drug Inactivation by Structure Modification	2.10e-02	5.20e-02	194	27	2	23467	Malignant cells	GSTP1,NME1
Aberration of the Drug's Therapeutic Target	5.30e-01	8.80e-01	194	90	1	23467	Malignant cells	NPM1
Epigenetic Alteration of DNA, RNA or Protein	7.30e-01	9.10e-01	194	455	3	23467	Malignant cells	GAPDH,SMC4,MALAT1
Irregularity in Drug Uptake and Drug Efflux	1.00e+00	1.00e+00	194	37	0	23467	Malignant cells

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group
	This dataset does not contain malignant cells, nor does it predict any miRNA that corresponds to the top10 DEGs.

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group of the post-treatment samples

motif	motif	NES	AUC	TF_highConf	Cell_type
	swissregulon__hs__ETV6	6.28	0.0851	ETV6 (directAnnotation).	Malignant cells
	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	5.73	0.0792	ELF2 (directAnnotation).	Malignant cells
	transfac_pro__M06660	5.32	0.0748	ZNF670 (directAnnotation).	Malignant cells
	hdpi__FLI1	4.62	0.0672	FLI1 (directAnnotation).	Malignant cells
	metacluster_141.4	4.51	0.0661	GLIS2 (directAnnotation).	Malignant cells
	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	4.36	0.0644	ETS2 (directAnnotation).	Malignant cells
	jaspar__MA1483.2	4.15	0.0623	ELF2 (directAnnotation).	Malignant cells
	taipale_tf_pairs__ETV2_DLX3_RSCGGAANNNNNNNTAATKR_CAP_repr	4.13	0.062	DLX3; ETV2 (directAnnotation).	Malignant cells
	metacluster_166.4	4.13	0.062	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__ETV5_FOXI1_RSCGGATGTTGN_CAP	3.97	0.0604	ETV5; FOXI1 (directAnnotation).	Malignant cells

Page: 1 2 3 4 5 6

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."